{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:08:51Z","timestamp":1783699731875,"version":"3.55.0"},"reference-count":53,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, affecting one-fourth of the adult population worldwide. Recent data found an association between MASLD and hypogonadism, but this relation in patients with type 2 diabetes mellitus (T2DM) is still unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate in men with T2DM the association between total testosterone (TT) and noninvasive indices of hepatic steatosis (Fatty Liver Index [FLI], Hepatic Steatosis Index [HSI], Dallas Steatosis Index [DSI]) and fibrosis (AST to Platelet Ratio Index [APRI], Fibrosis-4 Index [FIB-4]), and their predictive cutoff values in identifying hypogonadism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cross-sectional study on 189 men with T2DM, without history of liver diseases and alcoholism, recruited on an outpatient basis. Interventions were andrological evaluation, metabolic parameters, TT, and liver indices. The main outcome measures were comparison of steatosis and fibrosis indices with testosterone levels and presence of hypogonadism. Receiver operating characteristic curves were used to identify cutoff values of liver indices in predicting low testosterone (&amp;lt;12 nmol\/L).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>FLI, HSI, and DSI were negatively related with TT and were higher in the low-testosterone group than in the normal-testosterone group (FLI: 74.1 [61.4-93.5] vs 56.5 [32.1-78.2], P &amp;lt; .001; HSI: 41.5 [39.2-45.9] vs 40.1 [36.6-43.2], P = .005; DSI: 0.45 [\u22120.08-+1.04] vs \u22120.07 [\u22121.02-+0.58], P &amp;lt; .001). FLI and DSI also correlated with clinical symptoms of hypogonadism. No differences between groups were observed for APRI and FIB-4. FLI \u226563 was the best parameter as predictive index of low TT (sensitivity 73%, specificity 64%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We found an association between noninvasive indices of steatosis and hypogonadism in patients with T2DM. These indices could be used to direct the patients to andrological evaluation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad586","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:09:52Z","timestamp":1696511392000},"page":"e522-e530","source":"Crossref","is-referenced-by-count":6,"title":["Noninvasive Indices of MASLD Are Associated With Hypogonadism in Male Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-7617","authenticated-orcid":false,"given":"Nicola","family":"Caretta","sequence":"first","affiliation":[{"name":"Unit of Andrology and Reproductive Medicine, University Hospital of Padova , 35128 Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9390-6750","authenticated-orcid":false,"given":"Raffaele","family":"Scafa","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova , 35128 Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Graziani","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova , 35128 Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Crepaldi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Metabolic Diseases, University of Padova , 35128 Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Vedovato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Metabolic Diseases, University of Padova , 35128 Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Avogaro","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Metabolic Diseases, University of Padova , 35128 Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-8141","authenticated-orcid":false,"given":"Alberto","family":"Ferlin","sequence":"additional","affiliation":[{"name":"Unit of Andrology and Reproductive Medicine, University Hospital of Padova , 35128 Padova , Italy"},{"name":"Department of Medicine, University of Padova , 35128 Padova , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"issue":"1","key":"2024011817420552700_dgad586-B1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"2024011817420552700_dgad586-B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"2024011817420552700_dgad586-B3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"8","key":"2024011817420552700_dgad586-B4","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2337\/diacare.27.8.2057","article-title":"Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis","volume":"27","author":"Medina","year":"2004","journal-title":"Diabetes Care"},{"key":"2024011817420552700_dgad586-B5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metab Clin Exp"},{"issue":"9","key":"2024011817420552700_dgad586-B6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"2024011817420552700_dgad586-B7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cgh.2012.03.011","article-title":"Features, diagnosis, and treatment of nonalcoholic fatty liver disease","volume":"10","author":"Torres","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2024011817420552700_dgad586-B8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","article-title":"In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not","volume":"62","author":"Younossi","year":"2013","journal-title":"Metab Clin Exp"},{"issue":"7","key":"2024011817420552700_dgad586-B9","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed Nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"2024011817420552700_dgad586-B10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"2024011817420552700_dgad586-B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Ann Hepatol"},{"issue":"8","key":"2024011817420552700_dgad586-B12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH \u2014 current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2024011817420552700_dgad586-B13","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J Hepatol"},{"issue":"10","key":"2024011817420552700_dgad586-B14","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"2024011817420552700_dgad586-B15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"2024011817420552700_dgad586-B16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2265.1995.tb02040.x","article-title":"Hypothalamic-pituitary-testicular function in end-stage non-alcoholic liver disease before and after liver transplantation","volume":"43","author":"Handelsman","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2024011817420552700_dgad586-B17","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.22252","article-title":"Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor","volume":"47","author":"Lin","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"2024011817420552700_dgad586-B18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.metabol.2012.12.007","article-title":"Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense LDL, and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet","volume":"62","author":"Senmaru","year":"2013","journal-title":"Metab Clin Exp"},{"issue":"2","key":"2024011817420552700_dgad586-B19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2337\/db14-0249","article-title":"5\u03b1-Reductase Type 1 deficiency or inhibition predisposes to insulin resistance, hepatic steatosis, and liver fibrosis in rodents","volume":"64","author":"Livingstone","year":"2015","journal-title":"Diabetes"},{"issue":"2","key":"2024011817420552700_dgad586-B20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/liv.14652","article-title":"The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US men","volume":"41","author":"Phan","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"2024011817420552700_dgad586-B21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.23736\/S0391-1977.16.02570-0","article-title":"Hypogonadism and non-alcoholic fatty liver disease","volume":"42","author":"Mintziori","year":"2017","journal-title":"Minerva Endocrinol"},{"issue":"5","key":"2024011817420552700_dgad586-B22","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.dsx.2020.07.049","article-title":"Nonalcoholic fatty liver disease in males with low testosterone concentrations","volume":"14","author":"Polyzos","year":"2020","journal-title":"Diabetes Metab Syndr: Clin Res Rev"},{"issue":"11","key":"2024011817420552700_dgad586-B23","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/liv.13735","article-title":"Serum testosterone and non-alcoholic fatty liver disease in men and women in the US","volume":"38","author":"Yim","year":"2018","journal-title":"Liver Int"},{"issue":"1","key":"2024011817420552700_dgad586-B24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-230X-12-69","article-title":"A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease","volume":"12","author":"Kim","year":"2012","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"2024011817420552700_dgad586-B25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1179\/2045772314Y.0000000288","article-title":"Low testosterone and non-alcoholic fatty liver disease: evidence for their independent association in men with chronic spinal cord injury","volume":"39","author":"Barbonetti","year":"2016","journal-title":"J Spinal Cord Med"},{"issue":"2","key":"2024011817420552700_dgad586-B26","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cgh.2019.11.053","article-title":"Low Testosterone Is Associated with nonalcoholic steatohepatitis and fibrosis severity in men","volume":"19","author":"Sarkar","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2024011817420552700_dgad586-B27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4103\/aja.aja_68_19","article-title":"Histologically proven hepatic steatosis associates with lower testosterone levels in men with obesity","volume":"22","author":"Van de Velde","year":"2020","journal-title":"Asian J Androl"},{"issue":"9","key":"2024011817420552700_dgad586-B28","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s40618-021-01512-9","article-title":"Hypogonadism and liver fibrosis in HIV-infected patients","volume":"44","author":"Quiros-Roldan","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2024011817420552700_dgad586-B29","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s40618-022-01859-7","article-title":"Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE)","volume":"45","author":"Isidori","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2024011817420552700_dgad586-B30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/andr.12770","article-title":"European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males","volume":"8","author":"Corona","year":"2020","journal-title":"Andrology"},{"issue":"3","key":"2024011817420552700_dgad586-B31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s40618-022-01941-0","article-title":"Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes","volume":"46","author":"Caretta","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2024011817420552700_dgad586-B32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","article-title":"Development and evaluation of an abridged, 5\u2013item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction","volume":"11","author":"Rosen","year":"1999","journal-title":"Int J Impot Res"},{"issue":"5 Part 1","key":"2024011817420552700_dgad586-B33","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom Index for benign prostatic hyperplasia","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"issue":"3\u20134","key":"2024011817420552700_dgad586-B34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/13685530500283461","article-title":"Harmonized Italian version of the aging males\u2019 symptoms scale","volume":"8","author":"Valenti","year":"2005","journal-title":"Aging Male"},{"issue":"1","key":"2024011817420552700_dgad586-B35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"2024011817420552700_dgad586-B36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"9","key":"2024011817420552700_dgad586-B37","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.cgh.2020.01.020","article-title":"Dallas Steatosis Index identifies patients with nonalcoholic fatty liver disease","volume":"18","author":"McHenry","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"2024011817420552700_dgad586-B38","first-page":"477","article-title":"APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH","volume":"101","author":"Kruger","year":"2011","journal-title":"S Afr Med J"},{"issue":"9","key":"2024011817420552700_dgad586-B39","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"2024011817420552700_dgad586-B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/4947684","article-title":"Low Serum total testosterone is associated with non-alcoholic fatty liver disease in men but not in women with type 2 diabetes Mellitus","volume":"2022","author":"Zhang","year":"2022","journal-title":"Int J Endocrinol"},{"key":"2024011817420552700_dgad586-B41","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221106879","article-title":"Relationship between total testosterone, sex hormone\u2013binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis","volume":"13","author":"Mo","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2024011817420552700_dgad586-B42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024011817420552700_dgad586-B43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fendo.2019.00345","article-title":"Metabolic disorders and male hypogonadotropic hypogonadism","volume":"10","author":"Pivonello","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2024011817420552700_dgad586-B44","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.metabol.2009.05.010","article-title":"Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective akt phosphorylation in target tissues of adult male rat","volume":"58","author":"Muthusamy","year":"2009","journal-title":"Metab Clin Exp"},{"issue":"10","key":"2024011817420552700_dgad586-B45","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1210\/jc.2004-0784","article-title":"Effects of androgen therapy on adipose tissue and metabolism in older men","volume":"89","author":"Schroeder","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2024011817420552700_dgad586-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/294278","article-title":"Sex hormones and their receptors regulate liver energy homeostasis","volume":"2015","author":"Shen","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"4","key":"2024011817420552700_dgad586-B47","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4254\/wjh.v14.i4.754","article-title":"Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations","volume":"14","author":"Apostolov","year":"2022","journal-title":"World J Hepatol"},{"issue":"4","key":"2024011817420552700_dgad586-B48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40618-020-01381-8","article-title":"Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men","volume":"44","author":"Maseroli","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"(2)","key":"2024011817420552700_dgad586-B49","first-page":"e757","article-title":"The effect of testosterone replacement therapy on nonalcoholic fatty liver disease in older hypogonadal men","volume":"108","author":"Lee","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024011817420552700_dgad586-B50","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1507\/endocrj.EJ17-0225","article-title":"Free testosterone concentration is inversely associated with markers of liver fibrosis in men with type 2 diabetes mellitus","volume":"64","author":"Miyauchi","year":"2017","journal-title":"Endocr J"},{"issue":"6","key":"2024011817420552700_dgad586-B51","doi-asserted-by":"crossref","first-page":"e0251449","DOI":"10.1371\/journal.pone.0251449","article-title":"Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes","volume":"16","author":"Dayton","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"2024011817420552700_dgad586-B52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40618-020-01304-7","article-title":"Importance of total and measured free testosterone in diagnosis of male hypogonadism: immunoassay versus mass spectrometry in a population of healthy young\/middle-aged blood donors","volume":"44","author":"Agretti","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2024011817420552700_dgad586-B53","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1530\/EJE-11-1051","article-title":"Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men","volume":"166","author":"Huhtaniemi","year":"2012","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad586\/52298432\/dgad586.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/e522\/55530874\/dgad586.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/e522\/55530874\/dgad586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T17:45:57Z","timestamp":1705599957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/2\/e522\/7289548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,5]]},"published-print":{"date-parts":[[2024,1,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad586","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,10,5]]}}}